The 2023 Dry AMD Therapeutics Summit: The Only Industry-Focused Meeting for The Development of Dry AMD Therapeutics
For the first time, this meeting will delivered two tracks of content across preclinical and clinical development over three comprehensive days of content for anyone working in the dry AMD field. There was content from identifying appropriate targets in early preclinical research to lessons learned from the first approved product in the space.
New for 2023! A dedicated preclinical track focussed on improving the efficacy of in vitro and in vivo models to facilitate the translational success of dry AMD therapeutics. Learn from Nanoscope Therapeutics, Gyroscope Therapeutics, Ikarovec
New for 2023! A specific clinical track to drill down into the main challenges associated with clinical trial design and delivery of dry AMD therapeutics. Hear key insights from: Gyroscope Therapeutics, Novartis, Lineage Cell Therapeutics, and Allegro Ophthalmics
Leverage late-stage clinical updates and post approval patient updates to better understand drug efficacy, patient effects and long-term monitoring plans with IVERIC Bio, Inflammasome Therapeutics, Lineage Cell Therapeutics, and Allegro Ophthalmics
Utilize the latest advancements in imaging technology and AI to advance your understanding of end points and biomarkers for the early detection of intermediate AMD with the University of Toronto, Michael’s Hospital, Boehringer Ingelheim
Navigate the complex regulatory landscape to safeguard your approval process by hearing the key learnings from IVERIC Bio’s approval experience and gain understanding on the FDA’s perspective on combination therapy for dry AMD with Regenerative Patch Technologies